Maze Therapeutics, Inc. (MAZE) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $23.93: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 12.1:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 13.00; Below-average business quality; Below long-term trend.
Maze Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for kidney and metabolic diseases using its Compass genetics platform. Its two lead programs—MZE829 (Phase 2 for APOL1-mediated kidney disease) and MZE782 (Phase 2 ready... Read more
Sell if holding. Engine safety override at $23.93: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 12.1:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 13.00; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 47. Score 5.1/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 64d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-06-09Recent Developments — Maze Therapeutics, Inc.
Latest news
- NEWS Maze Therapeutics Q1 EPS $(0.45) Beats $(0.56) Estimate, Sales $20.000M Beat $9.286M Estimate — benzinga May 12, 2026 positive
- NEWS Maze Therapeutics Prices $150M Offering Of 5.54M Common Shares At $23.50 And 850K Pre-Funded Warrants At $23.499 — benzinga Apr 22, 2026 negative
- NEWS Truist Securities Maintains Buy on Maze Therapeutics, Lowers Price Target to $64 — benzinga Apr 14, 2026 neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineMZE82910-K Item 1A: 'We initiated a Phase 2 trial of MZE829, our most advanced lead program, in November 2024, dosed our first patient in February 2025 and reported positive topline clinical proof of concept data in March 2026'
Material Events(8-K, last 90d)
- 2026-03-25Item 5.02LOWBoard appointed Neil Kumar (co-founder and CEO of BridgeBio Pharma) as a Class I director effective March 27, 2026. No officer departures.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $23.93: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 12.1:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 13.00; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 47. Prior stop was $22.25. Score 5.1/10, moderate confidence.
Take-profit target: $54.41 (+127.4% upside). Prior stop was $22.25. Stop-loss: $22.25.
Concentration risk — Pipeline: MZE829; Quality below floor (3.4 < 4.0).
Maze Therapeutics, Inc. trades at a P/E of N/A (forward -7.1). TrendMatrix value score: 9.0/10. Verdict: Sell.
12 analysts cover MAZE with a consensus score of 4.3/5. Average price target: $63.
What does Maze Therapeutics, Inc. do?Maze Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for...
Maze Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for kidney and metabolic diseases using its Compass genetics platform. Its two lead programs—MZE829 (Phase 2 for APOL1-mediated kidney disease) and MZE782 (Phase 2 ready for PKU and CKD)—generate no product revenue; operations are funded by equity and a $200M Hercules term loan.